Search

Displaying results 2581 - 2590 of 10000 in total
  1. Drug

    Ospemifene

    go.drugbank.com/drugs/DB04938
    Approved

    FDA approved on February 26, 2013.

  2. Drug

    Bosutinib

    go.drugbank.com/drugs/DB06616
    ApprovedInvestigational

    ABL ratio on an international scale, with bosutinib treatment. … [A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving

  3. Drug

    Astemizole

    go.drugbank.com/drugs/DB00637
    ApprovedWithdrawn

    Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. … It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice.

  4. Drug

    Bisoctrizole

    go.drugbank.com/drugs/DB11262
    Approved

    Bisoctrizole is not approved by the FDA, but is approved in the EU and other parts of the world as a UV-filter in sunscreens, day care products and skin lightening products at a maximum concentration of

  5. Drug

    Efmoroctocog alfa

    go.drugbank.com/drugs/DB11607
    ApprovedInvestigational

    in the patient populations being studied [A31551]. … It is an antihemorrhagic agent used in replacement therapy for patients with haemophilia A (congenital factor VIII deficiency). It is suitable for all age groups.

  6. Drug

    Gestrinone

    go.drugbank.com/drugs/DB11619
    Approved

    Gestrinone was developed in the early 1970s and was tested clinically as a weekly oral contraceptive in Europe and North America. … is used primarily in the treatment of endometriosis.

  7. Drug

    Norepinephrine

    go.drugbank.com/drugs/DB00368
    ApprovedInvestigational

    It is also found in plants and is used pharmacologically as a sympathomimetic. … Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus.

    Products: N-EPI, Norepinephrine Bitartrate In Sodium Chloride
  8. Drug

    Nogapendekin alfa

    go.drugbank.com/drugs/DB18740
    ApprovedInvestigational

    [L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without … It is one of the active ingredients in Anktiva, a combination product also containing [inbakicept], where a single inbakicept is complexed with two nogapendekin alfa components.

  9. Drug

    Rusfertide

    go.drugbank.com/drugs/DB17724
    ApprovedInvestigational

    [L64098] The FDA approved rusfertide on August 28, 2026 for the treatment of erythrocytosis in adults with polycythemia vera, a blood cancer. … Rusfertide is a hepcidin mimetic used to treat erythrocytosis in adults with polycythemia vera.

  10. Drug

    Crisaborole

    go.drugbank.com/drugs/DB05219
    ApprovedInvestigational

    This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and older. … It reduces the local inflammation in the skin and prevents further exacerbation of the disease with a good safety profile.